Indivisible Partners Purchases New Shares in Merck & Co., Inc. $MRK

Key Points

• Indivisible Partners purchased a new stake of 12,823 shares (~$1.35M) in Merck during Q4, and institutional investors now own 76.07% of the company (Vanguard holds ~254.3M shares valued at $26.77B).
• Merck completed the acquisition of Terns Pharmaceuticals, adding clinical‑stage oncology assets, and recently beat quarterly EPS (reported ($1.28) vs. est. ($1.47)) and revenue ($16.29B vs. est. $15.85B), while guiding FY2026 EPS to 5.04–5.16.
• Company insiders have sold a total of 209,258 shares (~$25.1M) in the past 90 days, leaving insiders with just 0.17% ownership of the stock.

Indivisible Partners purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,823 shares of the company's stock, valued at approximately $1,350,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock valued at $26,770,014,000 after acquiring an additional 2,185,853 shares during the period. DLD Asset Management LP boosted its stake in Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc boosted its stake in Merck & Co., Inc. by 5.9% during the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock worth $1,733,923,000 after purchasing an additional 1,156,112 shares during the last quarter. Invesco Ltd. boosted its stake in Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Get Merck & Co., Inc. SMS alerts:

Sign Up

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck completed the acquisition of Terns Pharmaceuticals, adding clinical-stage oncology assets to its pipeline—a near-term catalyst for growth and synergy expectations. Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
• Positive Sentiment: Analysts and commentators point to continued KEYTRUDA-driven revenue and a strong pipeline; Merck delivered its fourth straight beat, supporting the view the stock may be undervalued on a longer-term basis. Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds
• Positive Sentiment: High-profile media support: Jim Cramer highlighted Merck’s solid quarter and said the stock is “starting to come back,” which can boost retail demand and sentiment. Jim Cramer on Merck & Co.: “The Stock’s Starting to Come Back”
• Neutral Sentiment: Institutional commentary: recent investor letters and analyst write-ups (e.g., Baron Capital coverage) review Merck as a core healthcare holding—useful background but not an immediate catalyst. What Makes Merck & Co. (MRK) an Investment Bet?
• Neutral Sentiment: Sector news: Pfizer beat Q1 estimates but faces a looming patent cliff; competitive results and sector rotation can influence pharma multiples and investor attention, creating mixed pressure across large peers including Merck. Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms
• Negative Sentiment: Technical/short-term risk: chart analysts warn a double-top breakdown and moving-average pressures that could produce a deeper correction, which may cap near-term upside despite fundamental positives. Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the business's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares in the company, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Michael Williams sold 5,000 shares of the business's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president owned 30,838 shares in the company, valued at $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 209,258 shares of company stock worth $25,101,593 over the last ninety days. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $113.21 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm has a market capitalization of $279.62 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 2.24 and a beta of 0.18. The company's 50-day moving average is $117.51 and its two-hundred day moving average is $107.91. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. Merck & Co., Inc.'s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts forecast that Merck & Co., Inc. will post 5.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRK. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wolfe Research raised shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price on the stock in a research note on Thursday, January 8th. Guggenheim lifted their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.